How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?

Key Takeaways AbbVie's Q2 beat was driven by strong Skyrizi and Rinvoq sales despite Humira erosion.Skyrizi sales rose 62% to $4.42B; Rinvoq sales climbed 41% to$ 2.03B, led by IBD growth.AbbVie raised Skyrizi 2025 sales guidance to $17.1B; Rinvoq remains on track for$ 8.2B.AbbVie (ABBV) delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer immunology medicines, Rinvoq and Skyriz ...